The knowledge-based development of immunotherapy tailored to treat both inherited and sporadic MSI cancers, comes in addition to the knowledge-based development of PARP inhibitors to treat both inherited and somatic BRCA1/2 deficient DNA double-stranded break-associated cancer [60]. Here, BRCA1 is linked to cancer.